Association of left ventricular hypertrophy with high-sensitive C-reactive protein in hemodialysis patients

International Urology and Nephrology

Volumn 45, Issue 6, 2013, Pages 1679-1686

  Monfared, Ali ^a,b   Salari, Arsalan ^c   Kazemnezhad, Ehsan ^a   Lebadi, Mohammadkazem ^a   Khosravi, Masoud ^a   Mehrjardi, Neda Kalantar ^a   Rahimifar, Shahrzad ^b   Amini, Nazly ^b  

^a GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Echocardiography; Hemodialysis; High sensitive C reactive protein; Left ventricular mass index

Indexed keywords

ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN;

ADULT; AGE; ARTICLE; BLOOD PRESSURE MEASUREMENT; C REACTIVE PROTEIN BLOOD LEVEL; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; INFLAMMATION; LEFT VENTRICULAR MASS INDEX; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTION; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ADULT; AGE FACTORS; AGED; BIOLOGICAL MARKERS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; ORGAN SIZE; RENAL DIALYSIS;

EID: 84890803949     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-012-0375-x     Document Type: Article

References (36)

1. Levey AS, Beto JA, Coronado BE et al (1998) Controlling the epidemic of cardiovascular disease in chronic renal disease. What do we know? What do we need to know? Where do we go from here? Am J Kidney Dis 32:853-906
2. Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 32(suppl 5):S112-S119
3. Berl T, Henrich W (2006) Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol 1:8-18
4. Fox ER, Benjamin EJ, Sarpong DF et al (2010) The relation of C-reactive protein to chronic kidney disease in African Americans: the Jackson Heart Study. BMC Nephrol 11:1
5. Stam F, van Guldener C, Schalkwijk CG et al (2003) Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity. Nephrol Dial Transplant 18(5):892-898
6. Chung A, Iheonunekwu N, Gilbert DT et al (2007) Cardiac disease in dialysis patients in a Jamaican Hospital echocardiographic findings that predict mortality. West Indian Med J 56(3):305
7. London GM (2002) Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant 17w(Suppl 1x):29-36
8. Parfrey PS, Griffiths SM, Harnett JD, Taylor R, King A, Hand J et al (1990) Outcome of congestive heart failure, dilated cardiomyopathy, hypertrophic hyperkinetic disease, and ischaemic heart disease in dialysis patients. Am J Nephrol 10:213-221
9. Pasceri V, Willerson JT, Yeh ET (2000) Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102(18):2165-2168
10. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1998) Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 97(5):425-428
11. Himmelfarb J, Stenvinkel P, Ikizler TA et al (2002) The elephant of uremia: oxidative stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62:1524-1538
12. Ridker PM (2003) Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107:363-369
13. Stenvinkel P, Lindholm B (2005) C-reactive protein in end-stage renal disease: are there reasons to measure it? Blood Purif 23:72-78
14. Harnett JD, Kent GM, Barre PE, Taylor R, Parfrey PS (1994) Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. J Am Soc Nephrol 4(7):1486-1490
15. Helal I, Zerelli L, Krid M, ElYounsi F et al (2012) Comparison of C-reactive protein and high-sensitivity C-reactive protein levels in patients on hemodialysis. Saudi J Kidney Dis Transpl 23(3):477-483
16. Pearson TA, Mensah GA, Alexander RW et al (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499-511
17. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N (1986) Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57(6):450-458
18. Memisoglu E, Yildiz A, Oflaz H et al (2005) Atherosclerosis and vascular calcification are independent predictors of left ventricular hypertrophy in chronic haemodialysis patients. Nephrol Dial Transplant 20:760-767
19. Parfrey PS (1999) Pathogenesis of cardiac disease in dialysis patients. Semin Dial 12:62-68
20. Glassock RJ, Pecoits-Filho R, Barberato SH (2009) Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol 4:S79-S91
21. London G (2001) Pathophysiology of cardiovascular damage in the early renal population. Nephrol Dial Transplant 16w(Suppl 12x):3-6
22. Katz AM (1990) Cardiomyopathy of overload: a major determinant of prognosis in congestive heart failure. N Engl J Med 322:100-110
23. Levin A, Singer J, Thompson CR, Ross H, Lewis M (1996) Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 27:347-354
24. Curtis BM, Parfrey PS (2005) Congestive heart failure in chronic kidney disease. Cardiol Clin 23:275-284
25. Stuveling EM, Hillege HL, Bakker SJL et al (2003) C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int 63:654-661
26. Yildiz A, Oflaz H, Pusuroglu H et al (2003) Left ventricular hypertrophy and endothelial dysfunction in chronic hemodialysis. Am J Kidney Dis 41(3):616-623
27. Ratto E, Leoncini G, Viazzi F, Falqui V et al (2007) C-reactive protein and target organ damage in untreated patients with primary hypertension. J Am Soc Hypertens 1(6):407-413
28. Dervisoglu E, Kozdag G, Etiler N, Kalender B (2012) Association of glomerular filtration rate and inflammation with left ventricular hypertrophy in chronic kidney disease patients. Hippokratia 16(2):137-142
29. Wanner C, Zimmermann J (2000) What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients? Semin Dial 13:174-175
30. Vidt DG (2006) Inflammation in renal disease. Am J Cardiol 16:20A-27A
31. Ferrucci L, Corsi A, Lauretani F et al (2005) The origins of age-related proinflammatory state. Blood 105:2294-2299
32. Ballou SP, Lozanski FB, Hodder S et al (1996) Quantitative and qualitative alterations of acute-phase proteins in healthy elderly persons. Age Ageing 25:224-230
33. Wester AL, Blaasaas KG, Wyller TB (2008) Is the concentration of C-reactive protein in bacteraemia associated with age? Immun Ageing 5:8
34. Middelton RJ, Parfrey PS, Foley RN (2001) Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol 12:1079-1084
35. Kim BS, Jeon DS, Shin MJ et al (2005) Persistent elevation of C-reactive protein may predict cardiac hypertrophy and dysfunction in patients maintained on hemodialysis. Am J Nephrol 25:189-195
36. Park CW, Shin YS, Kim CM et al (2002) Increased C-reactive protein following hemodialysis predicts cardiac hypertrophy in chronic hemodialysis patients. Am J Kidney Dis 40(6):1230-1239